

# Potential Best-In-Class Novel Topical Skin Cancer Treatment

The global non-melanoma skin cancer (NMSC) market is estimated to exceed \$450M<sup>1</sup>

- **Rapid and effective clearance of NMSC lesions**
- **Potential 1st-in-class topical treatment of facial sBCC lesions**
- **No adverse events. No side effects. No scarring**
- **IP covers both target and all developed antibodies**

## Rapid Clearance of Basal Cell Carcinoma

One of the first patients successfully treated with the Biosceptre Skin Cancer Ointment was a female with a papulonodular basal cell carcinoma (BCC) on her ear – a very serious condition. Disfiguring ear surgery was avoided by twice daily treatment with the Biosceptre Skin Cancer Ointment, clearing the lesion in 10 days. There has been no recurrence of BCC in 4½ years .



Day 1

Day 6

Day 16

## Market Information

- Basal Cell Carcinomas (BCCs) are the most common form of skin cancer with more than one million cases diagnosed annually
- Squamous Cell Carcinomas (SCCs) are the second most common form of skin cancer, with more than 250,000 cases diagnosed each year, resulting in approximately 2,500 deaths
- Surgical treatments are expensive and can result in scarring and discomfort, especially with multiple lesions on exposed areas of the body
- Topical treatments to date are dominated by Imiquimod 5% (Aldara) and 5-FU (Efudex). **Undesirable side-effects have been widely reported. Clearance rates for Aldara can be as low as 65% in large BCCs<sup>2</sup>**



**Biosceptre International Limited** is a public, unlisted biotechnology company based in Sydney, Australia and has exclusive global rights to nf-P2X<sub>7</sub>.

Biosceptre's findings have been verified by independent laboratories and offer exciting prospects for cancer diagnosis. This positions Biosceptre as a key player in the fields of cancer detection, diagnosis, monitoring and treatment.

## Efficacious

- Clearance rate for lesions was 85% in patients with superficial BCC and 81% in patients with nodular BCC
- Clearance rate for lesions in AK and SCC patients was 100%
- 0% recurrence to date (up to 5 years post treatment)

## Safe

- No adverse events or side effects recorded from more than 100 patients
- Base components are used widely in skin and/or dietary products

## Product Technical Summary

- Biosceptre has discovered and patented a novel cellular receptor, non-functional P2X<sub>7</sub> (nf-P2X<sub>7</sub>), which appears on all human cancers tested to date
- Functional P2X<sub>7</sub> is a cellular receptor responsible for programmed cell death. A structural change in the receptor has been identified rendering it non-functional in cancer cells
- Biosceptre has developed and patented a range of antibodies that specifically target nf-P2X<sub>7</sub>, initiating tumor cell death

## Development Summary

- Phase I/IIa protocol prepared for pre-IND submission
- Successful completion of informed consent testing in more than 100 patients
- Comprehensive pre-clinical package

## Biosceptre's Strong Intellectual Property Portfolio

- Patents granted in USA, Europe, Australia, New Zealand and South Africa
- Patent expiry 2027 with potential extension to 2032
- IP covers both target and all developed antibodies

## The Opportunity

Biosceptre is seeking a licensee for its Skin Cancer Ointment. Primary indications are sBCC and nBCC with additional utility in other NMSCs. It is expected that the successful licensee will complete the development program and bring the product to market.

<sup>1</sup> PharmaVentures

<sup>2</sup> [http://www.nps.org.au/health\\_professionals/publications/nps\\_radar/issues/archive/december\\_2006/imiquimod](http://www.nps.org.au/health_professionals/publications/nps_radar/issues/archive/december_2006/imiquimod)

## For more information:

**Mel Hemamda, Consultant**

PharmaVentures Ltd. | Magdalen Centre | Oxford Science Park | Oxford OX4 4GA | UK  
mel.hemamda@pharmaventures.com | +44 (0)1865 784 177